An Overview of Novavax's Influenza and Ebola Vaccines - Market Realist

An Overview of Novavax's Influenza and Ebola Vaccines
Market Realist
According to Novavax (NVAX), the value of the influenza vaccine market in developed markets is expected to reach $5.3 billion by 2021–2022 compared with $3.2 billion in 2012–2013. This shows the potential market opportunity for the company's influenza ...and more »